Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes

November 2013

Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes.

Gliptins are popular because they're taken orally once a day...and rarely cause hypoglycemia or weight gain.

In fact, nearly one in four diabetes patients take a gliptin.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Quality Measures More payers will recognize the value of pharmacists in improving the quality of patient care
Heart Failure bigger emphasis on preventing hospital admissions for heart failure
Diabetes Experts will debate whether gliptins (Onglyza, etc) increase cardiovascular risk in patients with type 2 diabetes
Contraceptives The new Minastrin 24 Fe and Lo Minastrin Fe (min-NASS-trin, norethindrone/ethinyl estradiol) are causing lots of confusion
Supplements whether the probiotic Cardioviva (CAR-dee-oh-VEE-vuh) lowers cholesterol
Substance Use Disorder new approaches to managing alcohol dependence
Dermatology Mirvaso (mer-VAY-soe) is a new brimonidine gel for rosacea
Pregnancy more questions about which cough, cold, and allergy meds to use during pregnancy and breastfeeding
Women's Health Reps will promote Brisdelle (BRIS-del) as a new nonhormonal treatment for hot flashes
Antithrombotics how to manage antiplatelet therapy in patients already taking anticoagulants
Pediatrics many parents exhibit signs of "fever phobia" and overuse antipyretics in their kids